Brazil's Fiocruz succeeds in technology transfer of GSK's triple vaccine

Brazil's Institute of Immunobiological Technology (Bio-Manguinhos/Fiocruz) announced the successful completion of a clinical trial that confirmed the immunogenicity and safety of its triple vaccine against measles, mumps, and rubella. The immunization treatment is the result of a technology transfer deal with U.K.-based major GlaxoSmithKline (GSK).

Dring the Phase III clinical study, three different batches of Bio-Manguinhos' triple vaccine helped induce high production of antibodies while causing only mild adverse events. This established the consistency of Bio-Manguinhos' manufacturing process and its non-inferiority compared to the control treatment produced using GSK's ingredients.


Related news
U.S.-based, China focused CASI Pharmaceuticals Inc., (Nasdaq.CASI) announced the signing of an exclusive distribution agreement with China Resources Guokang Pharmaceuticals Co., Ltd, (CRGK), focused on Evomela (melphalan hydrocholoride).
According to Carlos Murillo, president of Pfizer Brasil, the company has regained growth and expects to maintain it until 2020.
Pharmaceutical major AbbVie has recruited Máximo Guisasola as finance director for its South Region, which comprises Argentina, Chile, Paraguay, and Uruguay.
  • 1551635094299
  • Argentina,Chile,Uruguay,Paraguay
  • Company
Novartis’s dabrafenib and trametinib, Innovent Bio’s adalimumab biosimilar, Mundipharma Pharma’s pralatrexate, and Roche’s pertuzumab have been granted priority review and approval status by the Center for Evaluation (CDE) of National Medical Products Administration (NMPA), as gleaned by GBI.
GBI analyzed drug registrations granted last year by Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS).
Recent news
Alfonso Ramírez Cuéllar, president of the Budget Commission in Mexico’s House of Representatives, urged the Ministry of Finance and Public Credit (SHCP) to disclose the names of 10 pharmaceutical companies that have received contracts for 80% of the consolidated drug purchases during previous administrations.
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month approved Switzerland-based Roche’s hemophilia drug Hemlibra (emicizumab), as GBI analysis found.
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
According to GBI analysis, Ecuador’s National Agency for Health Regulation, Control and Surveillance (ARCSA) last month granted registration to Switzerland-based Ferring’s oral anti-inflammatory Cortiment (budesonide).
Switzerland-based giant Novartis AG has officially launched its Ultibro (indacaterol glycopyrronium bromide, powder for inhalation, hard capsules) and Seebri (glycopyrronium bromide, powder for inhalation, hard capsules) chronic obstructive pulmonary disease (COPD) maintenance therapies into the Chinese market.
  • 1552880244053
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
China-based vaccines specialist CanSino Biotechnology Inc., is moving to hold an initial public offering (IPO) of 5,725,200 H shares to the Hong Kong Stock Exchange (HKSE) Main Board from March 28, 2019 alongside another 51,523,400 H shares to the global market, with the price range currently at HKD 21 to HKD 22 per share.
Analytics Snapshot

The news, data, tools, and insights you need to make the best decisions.